학술논문
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
Document Type
Article
Author
Source
In: Cost Effectiveness and Resource Allocation . (Cost Effectiveness and Resource Allocation, December 2023, 21(1))
Subject
Language
English
ISSN
14787547